mProX™ Human LILRB4 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

LILRB4, also known as ILT3 or gp49B, has various applications in different fields. In the context of acute lymphoblastic leukemia (ALL), LILRB4 is implicated in acquired resistance to DOT1L inhibition, a potential therapeutic target for KMT2A-rearranged ALL. The loss of dependency on DOT1L-mediated H3K79 methylation in resistant cells is accompanied by the upregulation of LILRB4 and other myeloid-associated genes. In the field of infectious diseases, LILRB4 is involved in regulating the function of decidual myeloid-derived suppressor cells (dMDSCs) during Toxoplasma gondii infection. The downregulation of LILRB4 expression on dMDSCs leads to the dysfunction of these cells, potentially contributing to adverse pregnancy outcomes. In non-small cell lung cancer (NSCLC), high expression of LILRB4 on tumor-infiltrating cells, including myeloid-derived suppressor cells (MDSCs), is associated with poor prognosis and shorter overall survival and relapse-free survival. LILRB4 promotes tumor evasion and cancer progression in NSCLC. Additionally, LILRB4 is implicated in the development of myelomatous effusion (ME), a rare manifestation of extramedullary multiple myeloma (MM). Single-cell RNA sequencing analysis reveals the expression of LILRB4 in extramedullary-initiating cells (EMICs) associated with increased cellular proliferation and poor prognosis in MM. Furthermore, LILRB4 on NK cells interacts with fibronectin on target cells to attenuate natural cytotoxicity, suggesting a potential role in regulating NK cell activity in the tumor microenvironment.